Endometrial Squamous Cell Carcinoma
6
0
0
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
80%
4 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (6)
Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer
Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer